Ohio State launches pancreatic cancer trial via telehealth

Neoadjuvant ablative radiotherapy + chemo reduces risk of pancreatic cancer regrowth, stimulates immune system, cohort study finds

Adding targeted radiation to chemotherapy prior to surgery may offer better control of pancreatic tumors—potentially reducing the rate of recurrence after treatment, according to a cohort study from Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center.

July 11, 2025

Vol.51 No.27

Clinical Roundup

Rare pancreatic cancer shows strong response to immunotherapy

New research shows that a rare group of pancreatic cancer patients responded remarkably well to immunotherapy, a treatment typically considered ineffective for this cancer type.

July 03, 2025

Vol.51 No.26

Clinical Roundup

Scientists wipe out aggressive brain cancer tumors by targeting cellular “motors”

A potential treatment for glioblastoma crafted by scientists at The Wertheim UF Scripps Institute renders the deadly brain cancer newly sensitive to both radiation and chemotherapy drugs, and blocks the cancer’s ability to invade other tissue, a new study shows.

July 03, 2025

Vol.51 No.26

Clinical Roundup

Rucaparib maintenance therapy demonstrates PFS benefit for HRD-negative and HRD-positive ovarian cancer

First-line rucaparib maintenance treatment provided a progression-free survival benefit vs placebo in newly diagnosed, advanced, high-grade ovarian cancer after front-line platinum-based chemotherapy.

June 27, 2025

Vol.51 No.25

Drugs & Targets

FDA grants Breakthrough Therapy designation for daraxonrasib in pancreatic cancer

FDA has granted Breakthrough Therapy Designation to daraxonrasib, a RAS(ON) multi-selective inhibitor, for previously treated metastatic PDAC in patients with KRAS G12 mutations.

June 27, 2025

Vol.51 No.25

Cancer Policy

FDA halts new clinical trials that export Americans’ cells to foreign labs in hostile countries

FDA has announced that the agency will begin immediately reviewing all new clinical trials that include shipping American citizens’ living cells to “China and other hostile countries for genetic engineering and subsequent infusion” back into American patients.

June 20, 2025

Vol.51 No.24

By Claire Marie Porter

Ohio State launches pancreatic cancer trial via telehealth

YOU MAY BE INTERESTED IN

Neoadjuvant ablative radiotherapy + chemo reduces risk of pancreatic cancer regrowth, stimulates immune system, cohort study finds

Rare pancreatic cancer shows strong response to immunotherapy

Scientists wipe out aggressive brain cancer tumors by targeting cellular “motors”

Rucaparib maintenance therapy demonstrates PFS benefit for HRD-negative and HRD-positive ovarian cancer

FDA grants Breakthrough Therapy designation for daraxonrasib in pancreatic cancer

FDA halts new clinical trials that export Americans’ cells to foreign labs in hostile countries

Renew today!

Subscriber content

Never miss an issue!

Login